Both in Pharmaceuticals
Spyre Therapeutics vs Arrowhead Research
Over the past year SYRE returned +317.5% and ARWR returned +50.3%; their daily moves had a correlation of 0.30.
SYRE +317.5% ARWR +50.3%Growth of $1, one year, split-adjusted
| Metric | SYRE | ARWR |
|---|---|---|
| Price | $99.27 | $59.53 |
| Market cap | $9.28B | $8.41B |
| Today | +3.94% | −0.07% |
| 1 month | +7.1% | −4.5% |
| 6 months | +39.8% | −20.6% |
| Year to date | +203.0% | −10.3% |
| 1 year | +305.8% | +40.4% |
| Revenue growth (YoY) | — | +171.0% |
| Gross margin | — | 100.0% |
| Net margin | — | −258.2% |
| P/E (TTM) | — | — |
| Price / sales | — | 12.6× |
| Net cash | $1.15B | $737.9M |
| Dividend yield | — | — |
| Volatility (60d) | 59.2% | 45.1% |
| Short % of float | 15.6% | 8.1% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).